Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with 99mTc, 111In, and 125I

Journal of Medicinal Chemistry

Volumn 54, Issue 11, 2011, Pages 3817-3826

  Hofström, Camilla ^a   Orlova, Anna ^b   Altai, Mohamed ^b   Wangsell, Fredrik ^c   Gräslund, Torbjörn ^a   Tolmachev, Vladimir ^b  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; GLUTAMATE ACETYLTRANSFERASE; HEXAHISTIDINE; HISTIDINE; INDIUM 111; IODINE 125; RADIOISOTOPE; SCAFFOLD PROTEIN; TECHNETIUM 99M;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IN VIVO STUDY; ISOTOPE LABELING; LIVER; MOLECULAR IMAGING; MOUSE; NONHUMAN; PURIFICATION; RADIOACTIVITY;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CYSTEINE; FEMALE; GLUTAMIC ACID; HISTIDINE; INDIUM RADIOISOTOPES; IRON RADIOISOTOPES; LIVER; MICE; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; RADIOISOTOPES; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION;

EID: 79958148943     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200065e     Document Type: Article

References (40)

1. Kelloff, G. J.; Krohn, K. A.; Larson, S. M.; Weissleder, R.; Mankoff, D. A.; Hoffman, J. M.; Link, J. M.; Guyton, K. Z.; Eckelman, W. C.; Scher, H. I.; O'Shaughnessy, J.; Cheson, B. D.; Sigman, C. C.; Tatum, J. L.; Mills, G. Q.; Sullivan, D. C.; Woodcock, J. The progress and promise of molecular imaging probes in oncologic drug development. Clin. Cancer Res. 2005, 11, 7967-7985. (Pubitemid 41698738)
2. McLarty, K.; Reilly, R. M. Molecular imaging as a tool for personalized and targeted anticancer therapy. Clin. Pharmacol. Ther. 2007, 81, 420-424. (Pubitemid 46364494)
3. Tolmachev, V.; Stone-Elander, S.; Orlova, A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: Prospects and pitfalls. Lancet Oncol. 2010, 11, 992-1000.
4. Miao, Z.; Levi, J.; Cheng, Z. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids [Online early access]. DOI: 10.1007/s00726-010-0503-9. Published Online: Feb 21, 2010.
5. Wester, H. J.; Kessler, H. Molecular targeting with peptides or peptide-polymer conjugates: Just a question of size? J. Nucl. Med. 2005, 46, 1940-1945. (Pubitemid 46657438)
6. Nygren, P. A. Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 2008, 275, 2668-2676.
7. Löfblom, J.; Feldwisch, J.; Tolmachev, V.; Carlsson, J.; Ståhl, S.; Frejd, F. Y. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010, 584, 2670-2680.
8. Ahlgren, S.; Tolmachev, V. Radionuclide molecular imaging using Affibody molecules. Curr. Pharm. Biotechnol. 2010, 11, 581-589.
9. Block, H.; Maertens, B.; Spriestersbach, A.; Brinker, N.; Kubicek, J.; Fabis, R.; Labahn, J.; Schäfer, F. Immobilized-metal affinity chromatography( IMAC): A review. Methods Enzymol. 2009, 463, 439-473.
10. Waibel, R.; Alberto, R.; Willuda, J.; Finnern, R.; Schibli, R.; Stichelberger, A.; Egli, A.; Abram, U.; Mach, J. P.; Plücthun, A.; Schubiger, P. A. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotechnol. 1999, 17, 897-901. (Pubitemid 29416665)
11. Orlova, A.; Nilsson, F. Y.; Wikman, M.; Widström, C.; Ståhl, S.; Carlsson, J.; Tolmachev, V. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J. Nucl. Med. 2006, 47, 512-519. (Pubitemid 46768494)
12. 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J. Nucl. Med. 2006, 47, 1707-1716. (Pubitemid 47545038)
13. Zahnd, C.; Kawe, M.; Stumpp, M. T.; de Pasquale, C.; Tamaskovic, R.; Nagy-Davidescu, G.; Dreier, B.; Schibli, R.; Binz, H. K.; Waibel, R.; Plückthun, A. Efficient tumor targeting with highaffinity designed ankyrin repeat proteins: Effects of affinity and molecular size. Cancer Res. 2010, 70, 1595-1605.
14. 99mTc. Nucl. Med. Commun. 2001, 22, 1089-1094. (Pubitemid 33015974)
15. 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy(ADEPT). Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 1090-1096. (Pubitemid 39050175)
16. Ahlgren, S.; Orlova, A.; Rosik, D.; Sandström, M.; Sjöberg, A.; Baastrup, B.; Widmark, O.; Fant, G.; Feldwisch, J.; Tolmachev, V. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjugate Chem. 2008, 19, 235-243. (Pubitemid 351213855)
17. Ahlgren, S.; Wållberg, H.; Tran, T. A.; Widström, C.; Hjertman, M.; Abrahmsén, L.; Berndorff, D.; Dinkelborg, L. M.; Cyr, J. E.; Feldwisch, J.; Orlova, A.; Tolmachev, V. Targeting of HER2-expressing tumors using a site-specifically 99mTc-labeled recombinant Affibody molecule ZHER2:2395 with C-terminal engineered cysteine. J. Nucl. Med. 2009, 50, 781-789.
18. HER2:342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjugate Chem. 2007, 18, 1956-1964. (Pubitemid 350219996)
19. 99mTc-labeled anti-HER2. Bioconjugate Chem. 2008, 19, 2568-2576.
20. +, and show improved biodistribution. Bioconjugate Chem. 2010, 21, 2013-2022.
21. Ahlgren, S.; Andersson, K.; Tolmachev, V. Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. Nucl. Med. Biol. 2010, 37, 539-546.
22. Tolmachev, V.; Mume, E.; Sjöberg, S.; Frejd, F. Y.; Orlova, A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 692-701.
23. 68Ga-labeled affibody molecules. J. Nucl. Med. 2010, 51, 892-897.
24. Klaassen, C. D.; Aleksunes, L. M. Xenobiotic, bile acid, and cholesterol transporters: Function and regulation. Pharmacol. Rev. 2010, 62, 1-96.
25. Tran, T. A.; Rosik, D.; Abrahmsén, L.; Sandström, M.; Sjöberg, A.; Wållberg, H.; Ahlgren, S.; Orlova, A.; Tolmachev, V. Design, synthesis and biological evaluation of a HER2-specific affibody molecule for molecular imaging. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1864-1873.
26. Orlova, A.; Tolmachev, V.; Pehrson, R.; Lindborg, M.; Tran, T.; Sandström, M.; Nilsson, F. Y.; Wennborg, A.; Abrahmsén, L.; Feldwisch, J. Synthetic affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007, 67, 2178-2186. (Pubitemid 46424237)
27. 111In-ABY- 025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J. Nucl. Med. 2010, 51, 1131-1138.
28. 99mTc-labeled recombinant Affibody molecules improves their biodistribution and imaging properties. J. Nucl. Med. 2011, 52, 461-469.
29. Tolmachev, V.; Orlova, A. Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. Curr. Med. Chem. 2010, 17, 2636-55.
30. Pascal, R. R. Renal manifestations of extrarenal neoplasms. Hum. Pathol. 1980, 11, 7-17. (Pubitemid 10113938)
31. Abrams, H. L.; Spiro, R.; Goldstein, N.Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 1950, 3, 74-85.
32. Decristoforo, C.; Mather, S. J. 99m-Technetium-labelled peptide- HYNIC conjugates: Effects of lipophilicity and stability on biodistribution. Nucl. Med. Biol. 1999, 26, 389-396. (Pubitemid 29254025)
33. George, A. J.; Jamar, F.; Tai, M. S.; Heelan, B. T.; Adams, G. P.; McCartney, J. E.; Houston, L. L.; Weiner, L. M.; Oppermann, H.; Peters, A. M. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: Technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8358-8362.
34. 99TcO] apcitide: A technetium labeled peptide. Inorg. Chem. 2004, 43, 2867-2875.
35. Cyr, J. E.; Pearson, D. A.; Wilson, D. M.; Nelson, C. A.; Guaraldi, M.; Azure, M. T.; Lister-James, J.; Dinkelborg, L. M.; Dean, R. T. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. J. Med. Chem. 2007, 50, 1354-1364. (Pubitemid 46496334)
36. Wållberg, H.; Ahlgren, S.; Widström, C.; Orlova, A. Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(-Cys) Affibody molecule for targeting of HER2-expressing tumors. Mol. Imaging Biol. 2010, 12, 54-62.
37. 68Ga for PET imaging. Direct in vivo comparison with 111In-labelled analogue. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 1356-1367.
38. Mume, E.; Orlova, A.; Larsson, B.; Nilsson, A. S.; Nilsson, F. Y.; Sjöberg, S.; Tolmachev, V. Evaluation of((4-hydroxyphenyl)ethyl)- maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjugate Chem. 2005, 16, 1547-1555. (Pubitemid 41683137)
39. 18F]FBEM-ZHER2:342-Affibody molecule, a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.Eur. J.Nucl.Med.Mol. Imaging 2008, 35, 1008-1018.
40. Lundberg, E.; Brismar, H.; Gräslund, T. Selection and characterization of Affibody ligands to the transcription factor c-Jun. Biotechnol. Appl. Biochem. 2009, 52, 17-27.